ArticleEncephalitis (Seoul, Korea)2026
Long-term survival (≥2 years) in subacute sclerosing panencephalitis: a systematic review of prolonged survivors.
Article in Encephalitis (Seoul, Korea), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Subacute sclerosing panencephalitis (SSPE) is a progressive and often fatal disorder with highly variable survival. This systematic review aimed to characterize long-term survival (≥2 years), remission, and stabilization, and identify determinants of favorable outcomes. Methods: A systematic review was conducted according to PRISMA 2020 guidelines. Studies including confirmed SSPE cases were considered eligible for inclusion. Individual patient analysis was restricted to cases with ≥2 years of follow-up. Data were extracted at the patient and cohort levels. Results: Analysis of 77 patients demonstrated that survival beyond 2 years is achievable but variable. Survival distribution showed 44.2% surviving 2 to <5 years, 28.6% surviving 5 to <10 years, and 27.3% surviving ≥10 years. Although 62.3% initially achieved remission or stabilization, 31.2% later developed progression, severe disability, or death. Reported factors associated with prolonged survival included treatment responsiveness (62.3%), slow disease progression (24.7%), and relapsing-remitting or biphasic patterns (20.8%). Additional contributors were host-related factors (18.2%), adult-onset disease (10.4%), early diagnosis, and electroencephalographic improvement. Across 31 cohort studies, overall survival remained poor. Survival beyond 2 years was inconsistently reported and varied widely. Remission or stabilization was observed in some studies, but disease progression remained the predominant outcome. Mortality ranged from low to very high across cohorts. Reported factors associated with improved survival included slower disease progression, older age at onset, earlier stage at diagnosis, and use of therapies such as inosine pranobex and interferon. Conclusion: SSPE survival outcomes show marked heterogeneity. Although prolonged survival occurs in some, most patients have poor outcomes, emphasizing the importance of early diagnosis and the need for effective therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.